Innovative AI Tool Enhances Heart Disease Detection Using Standard ECG Data
A cutting-edge AI tool analyzes routine ECG data to detect hidden structural heart diseases, promising earlier diagnosis and treatment opportunities. Developed by Columbia University researchers, EchoNext offers a cost-effective, non-invasive method to identify patients needing further cardiac evaluation, potentially saving countless lives.
Recent advancements in artificial intelligence (AI) have led to the development of a novel, cost-effective screening tool capable of identifying hidden structural heart diseases from routine electrocardiogram (ECG) data. Traditionally, ECGs are employed to detect abnormal heart rhythms, blockages, and previous heart attacks, but they have limitations in diagnosing structural issues such as valve disease and cardiomyopathy. To bridge this gap, researchers at Columbia University Irving Medical Center and NewYork-Presbyterian created EchoNext, an AI-powered system that analyzes standard ECG readings to determine which patients should proceed with an echocardiogram—a more detailed, ultrasound-based heart imaging test.
The AI model was trained on over 1.2 million paired ECG and echocardiogram data from 230,000 patients, enabling it to spot signs of structural heart problems more accurately than many cardiologists, even with AI assistance. In a validation study across four hospital systems, including several NewYork-Presbyterian campuses, EchoNext demonstrated high accuracy in detecting conditions like heart failure, valve disease, pulmonary hypertension, and significant heart thickening. When compared directly with 13 cardiologists analyzing 3,200 ECGs, EchoNext correctly identified 77% of structural heart diseases, outperforming human experts with a 64% accuracy rate.
In real-world applications, the AI system screened nearly 85,000 patients who had not previously undergone echocardiography. It flagged over 7,500 individuals as high-risk, and during follow-up, about 55% of these patients subsequently received their first echocardiogram, leading to a diagnosis of structural heart disease in nearly three-quarters of them. This approach has the potential to significantly increase early detection, potentially saving many lives by enabling timely treatment. The team has also shared anonymized data to support further research and is conducting clinical trials to implement EchoNext in emergency settings. Overall, this innovation exemplifies how AI can transform cardiac screening, making it more accessible and effective worldwide.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
HDAC1 Enzyme Acts as a Tumor Suppressor in Aggressive T-Cell Lymphomas
New research reveals the tumor-suppressing role of HDAC1 enzyme in aggressive T-cell lymphomas, offering promising avenues for targeted therapies using epigenetic modulation.
Diabetes and Weight Loss Drug Semaglutide Shows Promise in Treating Liver Disease
Emerging research shows that semaglutide, a medication for diabetes and weight loss, may also improve liver health in patients with fatty liver disease, opening new horizons in treatment options.
Aligning Surgical Decisions with Older Adults' Goals to Improve Patient-Centered Care
A groundbreaking decision-making tool helps align surgical choices with older adults' personal health goals, promoting patient-centered care and improved outcomes.
Continued Use of Antiseizure Medications During Pregnancy Despite Risks
A recent study highlights the ongoing use of antiseizure medications during pregnancy, with some drugs posing known or uncertain risks to fetal development. The research calls for better management and awareness, especially among socioeconomically disadvantaged populations.